Objective. The aim of this study was to investigate the effect of umbilical cord mesenchymal stem cells (UC-MSCs) on circulating T follicular helper (cTfh) cells in primary SS (pSS) patients.
Introduction
Primary SS (pSS) is a chronic autoimmune disorder characterized by lymphocytic infiltration of salivary and lachrymal glands, leading to xerostomia and xerophthalmia. The prominent immune abnormalities in this disease are B cell overactivation that results in mass autoantibody production [1] . Also, germinal centre (GC)like structures have been identified in the salivary glands of pSS patients [2] , the presence of which correlates with the severity of inflammation and increased anti-Ro/SSA and anti-La/SSB autoantibody production [3] .
T follicular helper (Tfh) cells are a specialized CD4 + T cell subset that typically expresses CXC chemokine receptor 5 (CXCR5), inducible T cell co-stimulator (ICOS), programmed cell death protein 1 (PD-1), transcriptional repressor B cell lymphoma 6 (Bcl-6) and IL-21 [46] . They have been recognized as essential for B cell maturation and immunoglobulin production [7] . CD4 + CXCR5 + T cells in the blood, together with surface expression of ICOS and PD-1 alone or in combination, are generally accepted as circulating Tfh (cTfh) cells [8, 9] . Recent studies have shown that salivary gland epithelial cells from pSS patients are able to induce Tfh cell differentiation directly [10] . In addition, increased cTfh cell frequency has been reported in pSS and correlates with serum autoantibody levels and disease severity [11, 12] , indicating that Tfh cells may play a part in the pathogenesis of this disease. Mesenchymal stem cells (MSCs) are pluripotent stem cells with the capacity to differentiate into different cell lineages, such as osteoblasts, chondrocytes etc. [13, 14] . Furthermore, MSCs may modulate T and B lymphocytes, dendritic cells and natural killer cells, which makes them a promising alternative cell therapy for various autoimmune diseases, including SLE [1518] , RA [19, 20] and pSS [21] . We have previously shown the effectiveness and safety of allogeneic infusion of MSCs for refractory pSS [21] . Intriguingly, infusion of MSCs into non-obese diabetic (NOD) mice could significantly decrease the percentage of splenic CD4 + CXCR5 + Tfh cells [21] . However, whether
MSCs exert their therapeutic effect partly by inhibiting Tfh cells in pSS patients remains unclear. The aim of our study was to explore the effect of umbilical cord MSCs (UCMSCs) on cTfh cells and the underlying mechanisms.
Materials and methods

Patients and controls
Blood samples were collected from pSS patients admitted to the Department of Immunology and Rheumatology, Drum Tower Clinical Medical College of Nanjing Medical University. All patients fulfilled the AmericanEuropean Consensus Group criteria for pSS diagnosis [22] and they had no other autoimmune or systemic diseases. The European League Against Rheumatism (EULAR) SS Disease Activity Index (ESSDAI) score was assessed [23] at the time we examined the frequency of cTfh cells in pSS patients. Blood samples from age-and sex-matched healthy controls (HCs) were obtained from the Medical Examination Center of Drum Tower Clinical Medical College of Nanjing Medical University. This research was in compliance with the Declaration of Helsinki. The study was approved by the ethics committee of Drum Tower Clinical Medical College of Nanjing Medical University. All patients and HCs were informed and consented to this study. Detailed clinical characteristics are shown in Table 1 .
Isolation and culture of UC-MSCs
Fresh human umbilical cords were obtained from Drum Tower Clinical Medical College of Nanjing Medical University. UC-MSCs were prepared as described previously [18] . All UC-MSCs used in the experiment were derived from passages 35. Flow cytometric analysis showed CD29, CD44 and CD105 expression >95% in parallel with CD45, CD34, CD14 and HLA-DR expression <2%.
Co-culture of UC-MSCs with peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll density-gradient centrifugation. UCMSCs were co-cultured with 1 Â 10 6 PBMCs isolated from pSS patients or HCs stimulated with phytohaemagglutinin (PHA; 2 mg/ml; Sigma, St Louis, MO, USA) in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) for 3 days. In a trans-well system, UC-MSCs were cultivated in the lower chamber and PBMCs were seeded into the trans-well membrane of the inner chamber with 0.4 mm pore size (Corning, Corning, NY, USA).
Differentiation assay
Purified naive CD4 + T cells were isolated from PBMCs according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). UC-MSCs were co-cultured with 1 Â 10 6 naive CD4 + T cells for 4 days at a ratio of 1:10 under Tfh cell-polarizing conditions: 3 mg/ml soluble anti-CD3 (eBioscience, San Diego, CA, USA), 3 mg/ml anti-CD28 (eBioscience), 50 ng/ml recombinant IL-6 (rIL-6; PeproTech, Rocky Hill, NJ, USA), 50 ng/ml rIL-21 (Abcam, Cambridge, MA, USA), 20 ng/ml rIL-12 (BioLegend, San Diego, CA, USA), 10 mg/ml anti-IL-4 antibody (eBioscience) and 10 mg/ml anti-IFN-g antibody (eBioscience). An inhibitor of indoleamine 2,3-dioxygenase (IDO), 1-methyl-DL-tryptophan (1-MT; 100 mM; Sigma) or anti-IL-10 antibody (10 mg/ml; eBioscience) was added to the UC-MSC and Tfh cell differentiation co-culture system. To detect which factors involved in UC-MSC-mediated suppression, UC-MSCs were stimulated with PD-1 Fc (20 ng/ml; BioLegend) for 2 days and UC-MSCs were co-cultured with naive CD4 + T cells under Tfh cell-polarizing conditions or with anti-PDL1 antibody (10 mg/ml; BioLegend) for 2 days. To estimate whether pro-inflammatory mediators had an effect on the suppressive capacity of UC-MSCs, UC-MSCs were prestimulated with IFN-a (20 ng/ml; PeproTech, Rocky Hill, NJ, USA) or polyinosinicpolycytidylic acid (polyI:C; 100 mg/ml; Sigma) or lipopolysaccharide (LPS; 1 mg/ml; Sigma) for 24 h and Determination of anti-Ro/SSA and anti-La/SSB using ELISA Anti-Ro/SSA and anti-La/SSB autoantibodies were determined by ELISA (Euroimmun, Morris Plains, NJ, USA). The sensitivity of the ELISA kits was 1 RU/ml.
Determination of IL-10 using the Luminex cytokine assay
The IL-10 level in the supernatant was measured with a Cytokine Human Magnetic 7-Plex Panel assay (Millipore, Billerica, MA, USA) on a Luminex 100 system (Luminex, Austin, TX, USA) according to the manufacturer's instructions. The sensitivity was 1 pg/ml.
Flow cytometric analysis
The cell suspension was labelled with the following monoclonal antibodies: FITC-or phycoerythrin (PE)-conjugated anti-CD4, Alexa Fluor 647-conjugated anti-CXCR5 and PerCP-Cy5.5-conjugated anti-PD-1 (BD). For surface marker staining, cells were maintained in the dark at 4 C for 30 min. For intracellular staining, cell suspension was incubated for 15 min in the dark at 4 C with surface antibody. After permeabilization, cell suspension was incubated for 30 min in the dark at 4 C with PE-conjugated anti-Foxp3 (eBioscience). 
IDO activity assay
Kynurenine metabolites were estimated by reverse-phase HPLC. In brief, 400 ml of culture supernatant was diluted with 400 ml of potassium phosphate buffer (0.05 M, pH 6.0) and protein was precipitated with 100 ml of 2 M trichloroacetic acid. Three hundred microlitres of supernatant was then injected into an RP18 column and eluted with a degassed potassium phosphate solution (0.015 M, pH 6.4) containing 27 ml/l acetonitrile at a flow rate of 0.5 ml/min. Kynurenine was detected by an ultraviolet (UV) detector at a wavelength of 350 nm. Tryptophan concentration was measured using a fluorescence detector at an excitation wavelength of 284 nm and an emission wavelength of 365 nm. The values were referred to a standard curve with defined kynurenine and tryptophan concentrations (060 mM).
Statistical analysis
Data were summarized as mean (S.E.M.). Statistical significance was determined by Student's t-test and the correlation coefficient between Tfh cell concentration and clinical features were analysed by Spearman's rank test. All statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA). A P-value <0.05 was considered significantly significant.
Results
Positive correlation of cTfh cells with serum anti-La/ SSB level and ESSDAI in pSS patients First, we examined peripheral cTfh cell frequency in pSS patients and HCs. Flow cytometric analysis showed that the percentage of CD4 + CXCR5 + PD-1 + cTfh cells was significantly up-regulated in pSS patients [6.55% (S.E.M. 0.51) vs 2.32% (0.13), P < 0.01; Fig. 1A ]. Next, correlations between cTfh cell frequency and ESSDAI or autoantibody level were analysed. Among the 48 pSS patients, cTfh cell frequency was positively correlated with ESSDAI (r = 0.64, P < 0.001). In those patients with serum antiRo/SSA and La/SSB levels >2 RU/ml, cTfh cell frequency had a positive correlation with serum anti-La/SSB level (r = 0.50, P = 0.02), but not with anti-Ro/SSA level (r = 0.20, P = 0.20; Fig. 1B ). Anti-La/SSB is a more specific autoantibody for pSS patients and is related to disease activity and severity [24] , suggesting that enhanced cTfh cell frequency promoted the development of pSS, possibly by stimulating anti-La/SSB autoantibody production.
UC-MSCs inhibited the generation of cTfh cells in vitro
In order to test the immunomodulatory role of UC-MSCs in cTfh cells, PBMCs from both pSS patients and HCs were co-cultured with UC-MSCs. Fig. 2A S1B, available at Rheumatology Online), suggesting that UC-MSCs down-regulated cTfh cell frequency, possibly through the balance of CXCR5 + and CXCR5 À T cells. To explore the mechanism of UC-MSC-mediated immune suppression, PBMCs were co-cultured with UC-MSCs in a trans-well system. We found that there were no significant differences in inhibition of cTfh cell generation by UC-MSCs between cell-to-cell contact and the transwell system, suggesting that soluble factors secreted by UC-MSCs may play an important role in suppressing cTfh cell generation [38.38% (S.E.M. 3.58) vs 17.81% (3.53) vs 23.01% (3.07), P < 0.05; Fig. 2C ).
UC-MSCs inhibited the differentiation and proliferation of cTfh cells
Since UC-MSCs suppressed the generation of cTfh cells in pSS patients, we were interested in ascertaining whether this inhibitory effect was caused by affecting cTfh differentiation, proliferation or apoptosis. First, naive CD4 + T cells isolated from pSS patients were with activated CD4 + T cells. We also found that IDO expression by UC-MSCs was only a little higher when UCMSCs were stimulated with PD-1 (see supplementary Fig.  S3C , available at Rheumatology Online). Consistently, the addition of anti-PDL1 antibody to the UC-MSCs and cTfh cell differentiation co-culture system had no effect on the secretion of IDO (see supplementary Reportedly Toll-like receptor 3 (TLR3) and TLR4 are overexpressed in the labial salivary glands of pSS patients, especially in infiltrating mononuclear cells, acinar cells and ductal epithelial cells [26] . pSS patients also display their own IFN signature and immune complexes induce the production of IFN-a in pSS patients [27] . Therefore we investigated whether the ability of UCMSCs to suppress Tfh cell differentiation was affected in the presence of such pro-inflammatory mediators as IFN-a, polyI:C (TLR3 ligand) or LPS (TLR4 ligand). The results demonstrated that there were no differences in Anti-La/SSB is more relevant to organ involvement in pSS patients [24] , suggesting that cTfh cells in pSS patients might promote the development of this disease by helping B cells with the production of higher levels of antiLa/SSB. Current therapy for pSS is based mainly upon corticosteroids and immunosuppressants according to the degree of organ damage. However, long-term application of these conventional drugs could lead to severe adverse effects, including infection, diabetes, osteoporosis and caput femoris necrosis. Therefore the search for high-efficiency and low side-effect therapeutic approaches has been the focus of research. In recent years MSCs have attracted widespread attention and been regarded as a novel cell therapy for autoimmune diseases because of their immunomodulatory capacity and lower immunogenicity. We previously infused MSCs into 24 refractory pSS patients and found that all patients' symptoms improved after MSC transplantation, concomitant with reduced levels of serum anti-Ro/SSA and anti-La/SSB antibodies and decreased percentage of cTfh cell [21] [29] . It has been reported that Tfh cells in the blood promote antibody production, whereas Tfr cells strongly inhibit antibody production in mice [30] . In addition, Tfr cells may limit the GC reaction by Tfh cells and the amount of antigenspecific IgM, IgG1, IgG2b and IgA [29, 31] [37] . In our experiment, we found that the mRNA expression of IDO in the UC-MSC co-culture system was greatly 
UC-MSCs inhibit cTfh cells through IDO in pSS patients
increased and was accompanied by a higher level of IDO enzymic activity in the supernatant, indicating that IDO is the critical factor responsible for the suppressive function of MSCs on cTfh cells. This notion was confirmed by the addition of IDO inhibitor 1-MT, which reversed the inhibitory effect of UC-MSCs on Tfh cells. IDO is a ubiquitously expressed intracellular enzyme that degrades the essential amino acid tryptophan in mammals, catalysing the initial and rate-limiting step in the de novo biosynthesis of nicotinamide adenine dinucleotide [38] . Increased expression of IDO has been shown in MSCs following exposure to IFN-g [39, 40] , which was identified as the main mechanism of T cell suppression by human MSCs [39] . IDO may be involved in many aspects of MSC-mediated immune suppression, including a direct effect on T cells by tryptophan depletion or toxic metabolites of tryptophan [4143] ; an indirect effect through altered function of antigen-presenting cells, especially dendritic cells [44, 45] ; inducing the generation of Tregs [46, 47] and eliciting the conversion of monocytes into IL-10-secreting M2 immunosuppressive macrophages [48] .
Taken together, our findings suggest that UC-MSCs could reduce the generation of cTfh cells in pSS patients by inhibiting cTfh cell differentiation through the secretion of IDO. Our study provides support for the application of MSCs in some autoimmune diseases associated with cTfh cell abnormality and sheds light on the development of novel therapeutic approaches targeting cTfh cells. However, further studies are still needed to clarify the roles of cTfh cells in pSS patients in vivo and the exact mechanisms of IDO suppression on cTfh cells.
Rheumatology key messages
. Circulating Tfh cells might be involved in the pathogenesis of primary SS. . Umbilical cord mesenchymal stem cells exhibited a therapeutic effect on primary SS patients by inhibiting circulating Tfh cell generation. 
